Serological COVID-19 ELISA kitIcosagen Covid-19 ELISA kit provides a rapid and easy method for semiquantitative determination of both IgG and IgM antibodies against SARS-CoV-2 (2019-nCoV) Spike and Nucleocapsid proteins in human sera and plasma.
APPLICATIONThe kit includes reagents necessary to analyze SARS-CoV-2 specific antibodies in up to 46 samples using one kit. ELISA titers can be determined in 23 serum or plasma samples.
Antigen-coated (S1 and N) microplate wells
INTENDED USEThe enzyme-linked immunosorbent assay (ELISA) provides semiquantitative in vitro determination of human antibodies of the immunoglobulin class IgG and IgM against SARS-CoV-2 in human serum or plasma to support the diagnosis of SARS-CoV-2 infection and constitutes a supplement to the direct pathogen detection. Serological analysis can be applied to collect epidemiological data.
CROSS-REACTIVITYThe Icosagen Covid-19 ELISA kit was evaluated for potential cross-reactivity from a total of 90 specimens representing 4 different groups. All 90 specimens showed no cross-reactivity.
HIV+ (human immunodeficiency virus)
HCV+ (hepatitis C virus)
HBV+ (hepatitis B virus)
CLINICAL PERFORMANCETotal of 296 specimens were tested using the Icosagen Covid-19 ELISA kit, of which 123 specimens were from PCR-positive group for SARS-CoV-2, and 173 serum specimens from pre-Covid-19 period or PCR-negative samples were used as negative control.
The sensitivity, specificity, accuracy, positive percent agreement (PPA) and negative percent agreement (NPA) values for the Icosagen Covid-19 ELISA kit are shown in Table 7.The results are presented in the following Table: